Related Experiment Video

Updated: May 31, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Prasinezumab: what have we learned from PASADENA and PADOVA?

Thomas Foltynie1

  • 1UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.

Lancet (London, England)
|May 28, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein
08:04

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Related Experiment Videos

Last Updated: May 31, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein
08:04

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Articles linked to this work by shared authors, journal, and citation graph.

Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data.

BMJ neurology open·2026

Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Clinical prognostic indicators in multiple system atrophy.

Brain : a journal of neurology·2026

Optimal Deep Brain Stimulation Locations for Gilles de la Tourette Syndrome.

medRxiv : the preprint server for health sciences·2026

Peripheral and CSF protein quantification in Parkinson's disease and multiple system atrophy-the nucleic acid-linked immuno-sandwich assay.

Brain communications·2026

The promise of GLP-1 receptor agonists for neurodegenerative diseases.

The Journal of clinical investigation·2026

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Development and frontier trends of pancreaticojejunostomy over the past 26 years: bibliometric and visual analysis.

Gland surgery·2026

Mining and engineering of active PB transposons in Hymenoptera.

Synthetic and systems biotechnology·2026

Expanded tibiae enhance male mating success in the damselfly Platycnemis phyllopoda.

iScience·2026

Bite force estimates and morphological correlations of jaw muscles in parrots.

Anatomical record (Hoboken, N.J. : 2007)·2026

Molecular characterization of parabrachial neurons in Xenopus laevis and Silurana tropicalis: evolutionary conservation and sex-specific differences.

Journal of neurophysiology·2026

Biotype dynamics of the common house mosquito Culex pipiens in the anthropogenic environment in winter: a citizen science approach.

Scientific reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us